Frazier Management LLC maintained its position in Cidara Therapeutics, Inc. (NASDAQ:CDTX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,312,258 shares of the biotechnology company’s stock at the end of the second quarter. Cidara Therapeutics comprises 5.0% of Frazier Management LLC’s portfolio, making the stock its 6th biggest holding. Frazier Management LLC owned 7.78% of Cidara Therapeutics worth $9,842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Trexquant Investment LP bought a new position in shares of Cidara Therapeutics during the 2nd quarter valued at approximately $110,000. Citadel Advisors LLC purchased a new stake in shares of Cidara Therapeutics during the 2nd quarter valued at approximately $129,000. Teachers Advisors LLC lifted its stake in shares of Cidara Therapeutics by 17.5% during the 4th quarter. Teachers Advisors LLC now owns 16,524 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 2,458 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Cidara Therapeutics by 455.6% during the 1st quarter. JPMorgan Chase & Co. now owns 25,639 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 21,024 shares in the last quarter. Finally, Spark Investment Management LLC purchased a new stake in shares of Cidara Therapeutics during the 1st quarter valued at approximately $227,000. 66.10% of the stock is owned by hedge funds and other institutional investors.

In other Cidara Therapeutics news, CEO Jeffrey Stein bought 7,350 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was bought at an average cost of $6.79 per share, for a total transaction of $49,906.50. Following the completion of the transaction, the chief executive officer now owns 51,851 shares of the company’s stock, valued at approximately $352,068.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 18.90% of the company’s stock.

A number of analysts recently commented on the stock. Cantor Fitzgerald restated a “buy” rating and set a $15.00 price target on shares of Cidara Therapeutics in a research note on Tuesday, September 26th. ValuEngine cut shares of Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Zacks Investment Research cut shares of Cidara Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, WBB Securities upgraded shares of Cidara Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $13.14.

COPYRIGHT VIOLATION NOTICE: “Cidara Therapeutics, Inc. (CDTX) Position Maintained by Frazier Management LLC” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/cidara-therapeutics-inc-cdtx-position-maintained-by-frazier-management-llc/1613078.html.

Shares of Cidara Therapeutics, Inc. (NASDAQ CDTX) traded down 1.88% during mid-day trading on Friday, hitting $7.85. 24,837 shares of the company were exchanged. Cidara Therapeutics, Inc. has a 52 week low of $5.60 and a 52 week high of $11.85. The company’s market capitalization is $132.37 million. The company has a 50 day moving average of $7.19 and a 200 day moving average of $7.07.

Cidara Therapeutics (NASDAQ:CDTX) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.08). Equities analysts anticipate that Cidara Therapeutics, Inc. will post ($3.62) earnings per share for the current year.

Cidara Therapeutics Profile

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Want to see what other hedge funds are holding CDTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cidara Therapeutics, Inc. (NASDAQ:CDTX).

Institutional Ownership by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.